Eagle Pharma (EGRX) Sell Off Overdone - RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500, Dow futures attempt recovery ahead of inflation report
- Oracle raises full year profit guidance, stock rises after hours
- Oil surges 6%, Brent and US crude both surpass $100 on more tanker attacks
- Analysts split on Apple after foldable iPhone Duo debut
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- White House copper tariff plan stalls amid affordability concerns, sources say
- Micron's Taiwan workers to get rewards worth up to 68 months of pay
- Crude Inventory 0.4M Barrels Last Week - EIA
- Vertiv shares drop on acquisition skepticism, AI pullback
- S&P 500, Dow futures attempt recovery ahead of inflation report
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Eagle Pharmaceuticals (EGRX) PT Lowered to $98 at Piper Jaffray Following CRL
March 18, 2016 12:07 PM EDTPiper Jaffray analyst David Amsellem lowered his price target on Eagle Pharmaceuticals (NASDAQ: EGRX) to $98.00 (from $121.00) but maintained an Overweight rating after the company received a complete response letter (CRL) from the FDA related to its NDA for Kangio, its ready-to-use (RTU) form of bivalirudin. The... More
Mizuho Securities Cuts Price Target on Eagle Pharmaceuticals (EGRX) as Kangio is Delayed
March 18, 2016 11:13 AM EDTMizuho Securities maintained a Buy rating on Eagle Pharmaceuticals (NASDAQ: EGRX), and cut the price target to $71.00 (from $81.00), on Kangio Delay. Eagle received a complete response letter (CRL) on Kangio, a reformulated version of MDCO's Angiomax. According to the letter, FDA wants further... More
Eagle Pharmaceuticals (EGRX) Announces Receipt of FDA Complete Response Letter for KANGIO NDA
March 18, 2016 6:52 AM EDTEagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its KANGIO (bivalirudin injection), 505(b)(2) New Drug Application for a ready-to-use (RTU), stable liquid intravenous formulation of 5 mg/mL bivalirudin in a 50-mL vial... More
